Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Somatic frameshift mutations in calreticulin (CALR) are key drivers of myelofibrosis.
• CALR mutations are classified as Type 1 (del52) or Type 2 (ins5), each with distinct clinical implications.
• Current treatments like tyrosine kinase inhibitors lack specificity and durability.

Purpose of the Study:

• To investigate the efficacy of dual antibody targeting strategies specific for Type 1 versus Type 2 CALR mutations.
• To evaluate the potential for ultra-precision medicine in treating myelofibrosis.

Main Methods:

• In vitro studies using primary megakaryocyte progenitors.
• In vivo studies in a humanized ossicle microenvironment and xenograft models.
• Assessment of STAT5, ERK, and JAK2 phosphorylation.
• Evaluation of CALR dimerization and response to antibody therapy and ruxolitinib.

Main Results:

• Dual antibody targeting of Type 1 (del52) CALR mutant showed superior eradication of megakaryocyte progenitors and improved survival in xenograft models compared to single-agent therapy.
• Dual targeting effectively blocked constitutive STAT5 and ERK phosphorylation and prevented JAK2 phosphorylation, overcoming ruxolitinib resistance.
• Type 2 mutations exhibited increased CALR dimerization and partial resistance to antibody targeting, but were impacted by a ruxolitinib triple combination.

Conclusions:

• Ultra-precision medicine approaches tailored to specific CALR mutation types (Type 1 or Type 2) are necessary for maximal efficacy in myelofibrosis treatment.
• Targeted strategies can achieve complete blockade of JAK/STAT signaling, offering improved patient management and therapeutic outcomes.